
Lily M. Park,1 Joanne Lannigan,2 Maria C. Jaimes3*

1Research and Development, Cytek Biosciences, Inc., Fremont, California, 94538-6407,
2Flow Cytometry Support Services, LLC, Alexandria, Virginia, 22314,
3Research and Development, Cytek Biosciences, Inc., Fremont, California, 94538-6407,

Received 3 June 2020; Revised 27 July 2020; Accepted 17 August 2020

Additional Supporting Information may be found in the online version of this article.

*Correspondence to: Maria C. Jaimes, Research and Development, Cytek Biosciences, Inc., 46107 Landing Parkway, Fremont, CA 94538-6407.
Email: mjaimes@cytekbio.com

Published online in Wiley Online Library (wileyonlinelibrary.com)
DOI: 10.1002/cyto.a.24213


This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PURPOSE AND APPROPRIATE SAMPLE TYPES

This 40-color flow cytometry-based panel was developed for in-depth immunophenotyping of the major cell subsets present in human peripheral blood. Sample availability can often be limited, especially in cases of clinical trial material, when multiple types of testing are required from a single sample or timepoint. Maximizing the amount of information that can be obtained from a single sample not only provides more in-depth characterization of the immune system but also serves to address the issue of limited sample availability. The panel presented here identifies CD4 T cells, CD8 T cells, regulatory T cells, γδ T cells, NKT-like cells, B cells, NK cells, monocytes and dendritic cells. For each specific cell type, the panel includes markers for further characterization by including a selection of activation and differentiation markers, as well as chemokine receptors. Moreover, the combination of multiple markers in one tube might lead to the discovery of new immune phenotypes and their relevance in certain diseases. Of note, this panel was designed to include only surface markers to avoid the need for fixation and permeabilization steps. The panel can be used for studies aimed at characterizing the immune response in the context of infectious or autoimmune diseases, monitoring cancer patients on immuno- or chemotherapy, and discovery of unique and targetable biomarkers. Different from all previously published OMIPs, this panel was developed using a full spectrum flow cytometer, a technology that has allowed the effective use of 40 fluorescent markers in a single panel. The panel was developed using cryopreserved human peripheral blood mononuclear cells (PBMC) from healthy adults (Table 1). Although we have not tested the panel on fresh PBMCs or whole blood, it is anticipated that the panel could be used in those sample preparations without further optimization. © 2020 Cytek Biosciences, Inc. Cytometry Part A published by Wiley Periodicals LLC on behalf of International Society for Advancement of Cytometry.

Key terms
Aurora; broad immunophenotyping; full spectrum; high-dimensional flow cytometry; OMIP; spectral; PBMCs

BACKGROUND

The need to understand the mechanisms and pathways of immune evasion seen either post immunotherapy or during natural immune responses to cancer, autoimmunity, and infectious diseases, requires methods and protocols which will enable a deeper profiling of the immune system. Greater characterization of immune subpopulations allows for more informed decisions regarding the identification of targetable biomarkers and the development of new therapeutic approaches. (1-4)

Unraveling the complexity of the human immune response requires the ability to perform high-throughput, in-depth analysis, at the single cell and population levels. Flow cytometry has sought to address this need by allowing the characterization of single-cell protein expression, through the binding of fluorochrome-labeled antibodies.
OMIP

to specific markers of interest. Over the years, manufacturers have increased the capabilities of flow cytometers through the incorporation of additional lasers and detectors, allowing detection of greater numbers of markers per cell. Concurrently, reagent manufacturers have worked to provide additional fluorophores to meet the demands of this rapidly expanding field. This has led to panel expansion over the last two decades, with a 17-color assay reported in 2004 (5) and up to 28 colors in more recent years (6-11). With the arrival of mass cytometry in 2009 (12), the number of markers assessed was expanded to 32, using metal-conjugated antibodies (13), and most recently a panel using 43 markers has been published (14).

In contrast to conventional flow cytometry, which primarily measures the peak emission of each fluorochrome, full spectrum flow cytometry measures the entire emission spectra for every fluorochrome, across all laser lines. As a result of collecting substantially more information about each cell, full spectrum flow cytometry is well suited to the development of highly multiparametric panels. Reports of applying the concepts of measuring fluorescence spectra by flow cytometry can be found as early as the 1970s (15), which was followed by a number of subsequent publications in later years (16-20). In order to expand the number of fluorochromes beyond the 28-color mark, a very high level of detail is needed to distinguish fluorochromes whose spectral signatures, particularly their peak emissions, are similar. This level of detail requires high-quality signals, low noise, and excitation specific full-emission profiles. It also requires extremely careful panel design and optimization. Here, we define full spectrum flow cytometry as measuring the entire fluorochrome emission, from ultraviolet to near-infrared, across multiple lasers using many more detectors, when compared to a conventional flow cytometer. This produces very specific spectral fingerprints that are used to mathematically distinguish one fluorochrome from another, even when their maximum emissions are very similar. Leveraging this full spectrum technology in a five-laser system, the ability to combine 30–40 fluorescently labeled antibodies becomes possible using a fluorescence-based flow cytometer.

As mentioned previously, mass cytometry is also capable of assessing similarly high numbers of parameters. Currently, this technology has the advantage of additional detection channels to accommodate bar coding schemes for sample pooling, and as a more mature technology, high complexity panels using mass cytometry have been previously published and are widely available, including the publication of multiple OMIPs (21-24). However, limitations such as sample throughput, cell transmission efficiency, and overall cost of ownership have impacted the practicality, and broader adoption, of this technology in some laboratory environments (25-27). Spectral flow cytometers share a very common workflow with conventional flow cytometers and are therefore not hindered by these limitations. However, there are no previously published reports of panels beyond 28 fluorescent parameters, a fact which further supports the need for a fluorescent OMIP panel of this complexity.

The panel presented in this OMIP examines the frequency of CD4 and CD8 T cells, regulatory T cells (T_{reg}), γδ T cells, NKT-like cells, B cells, NK cells, monocytes, basophils, innate lymphoid cells (ILCs), and dendritic cells. Additional markers allow for the characterization of the main B and T cell subsets—naive, memory, and effector—as well as putative T helper subsets. Dead cells were excluded using a viability dye (LIVE/Dead Fixable Blue). The following markers were used to characterize the indicated cell types: CD45 for all leukocytes; pan-γδ TCR for γδ T cells; CD3, CD4, and CD8 for the main T cell populations; CD19 and CD20 for B cells; CD16 and CD56 for NK cells; CD123 and HLA-DR for basophils; lineage markers and CD127 for total ILCs; and CD14 and CD16 for monocytes.

NK cells were identified by expression of CD56 (neural cell adhesion molecule [NCAM]) and CD16 (FcyRIII) (28), while CD2 was used to identify NK cells most likely to be involved in cytotoxicity (29). We included two natural cytotoxicity receptors (NCRs), NKG2D (natural killer group 2, member D [CD314]) and Nkp30 (CD337); as well as the inhibitory receptor NKG2A (CD159a), identified as a possible target for immunotherapy (30), and the activation receptor NKG2C (CD159c) known to be relevant for NK cells in infectious diseases and vaccine effector response (31). CD57 was included as a maturation marker for NK cells, identifying cells with potent cytotoxic and reduced replicative potential (32). CD56 was further used for the identification of NKT-like cells, defined as CD56^+CD3^−, as cells with this phenotype might play a role in infectious diseases (33).

γδ T cells are regarded as an important bridge between the innate and adaptive immune systems because their response precedes adaptive immunity, making γδ T cells a unique component of the immune system (34-36). They are also associated with major autoimmune rheumatic diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, systemic lupus erythematosus, and scleroderma (37). Although we included CD16 and CD56 to define NK cell subsets, CD16 and CD56 are also associated with an activated phenotype in γδ T cells (6,38). γδ T cells have also been shown to have effector/memory subsets based on expression of CD45RA, CD27, and CCR7 (39).

To characterize T cells, the memory and differentiation markers CD45RA, CCR7, CD27, and CD28 were used. Using CD45RA and CCR7, T cells can be classified into naïve (CD45RA^+CCR7^−), central memory (CD45RA^−CCR7^+), effector memory (CD45RA^−CCR7^−), and terminal effector memory (CD45RA^−CCR7^−) subsets (40,41). The addition of CD27 and CD28 allows further refinement of those subsets, identifying early effector (CD45RA^−CCR7^−CD28^−CD27^−), early-like effector (CD45RA^−CCR7^−CD28^+CD27^−), intermediate effector (CD45RA^−CCR7^−CD28^+CD27^+), terminal effector (CD45RA^−CCR7^−CD28^−CD27^+), and RA-terminal effector (CD45RA^−CCR7^−CD28^+CD27^+) (42,43).

Other surface markers, including CD127, CD95, PD-1, CD57, CD38, and HLA-DR, were included to further characterize T cell subsets (1,44,45). The IL-7 receptor (CD127) is involved in homeostatic proliferation and survival of memory T cell precursors (46), while CD57 is indicative of cell senescence, failure to proliferate, and susceptibility to activation-induced cell death (47,48). CD38 and HLA-DR were included
as T cell activation markers (49). Viral infections such as HIV-1, dengue virus, or influenza lead to increased frequencies of CD38^HLA-DR^ activated T cells (50,51), PD-1 and CD95 are both upregulated in activated T cells (52). The inhibitory receptor PD-1 is crucial for the regulation of immune responses and to avoid excessive immune activation (53).

In order to identify Tregs, we used CD25 (IL-2Rα) and CD127 (IL-7Rα) markers without the inclusion of FoxP3, which requires intracellular staining. Previous studies have shown that CD25^hiCD127^lo/-CD4^+ T cells are a good correlate of Tregs (54,55), although this strategy may over- or underestimate their frequency. It has been reported that Tregs can be further subsetted based on CD39 expression (7,56,57) and that CD39^+ Tregs might play a role in certain autoimmune diseases like multiple sclerosis (58).

CD27 and IgD were chosen for identification of naive (IgD^CD27^), marginal zone-like (IgD^CD27^) and memory (IgD^CD27^) B cells as previously described (59). Marginal zone-like B cells can be further divided into IgM^+ marginal zone and IgD only memory B cells (8). When used in combination, CD24 and CD38 distinguish memory (CD24^hiCD38^neg), naive (CD24^intCD38^int), and transitional (CD24^intCD38^hi) B cells, and have been used for regulatory B cell identification (60,61). Plasmablasts can be identified based on expression of CD19, CD20, CD27, and CD38 (62). Memory B cells express increased levels of CXCR3 (72).

Chemokine receptors are important for the migration and positioning of immune cells (64). This panel includes CCR5, CCR6, CXCR3, and CXCR5. CCR5 is expressed by activated and memory T cells (65), γδ T cells (66), and Tregs (67). On human T cells, CCR6 is attributed to a Th17 (RORIγT) phenotype (68). On B cells, CCR6 expression is restricted to functionally mature cells capable of responding to antigen challenge (69). CXCR3 has been reported to be necessary for T cell clustering around antigen presenting cells and T cell bystander activation (70) and also to be expressed on subsets of γδ T cells (66). CXCR5 interacts with CXCL13, which promotes T cell trafficking to B cell follicles and germinal centers. These are crucial sites for the generation of high-affinity antibody responses (71). Moreover, it has been shown that chronic inflammation leads to modulation of chemokine receptor expression on peripheral blood B cells. In patients with rheumatoid arthritis, B cells show decreased expression of CXCR5 and CCR6 and increased levels of CXCR3 (72).

Monocyte subsets were identified using CD14 (lipopolysaccharide binding protein) and CD16 (FcγRIII). These two markers allow the identification of classical monocytes.

<table>
<thead>
<tr>
<th>Species</th>
<th>Cell type</th>
<th>Cross references</th>
</tr>
</thead>
</table>

**Figure 1.** A. Manual gating strategy. The gating strategy used to identify the main cellular subsets is presented. Arrows are used to visualize the relationships across plots, and numbers are used to call attention to populations described here. After doublets and dead cells were excluded, basophils (1) were delineated as CD45^−CD123^HLA-DR^+. Lymphocytes and monocytes (2) were gated based on FSC-SSC-A properties. Monocytes (3) were then identified from the CD3^−^TCR^−^ population (12). CD19^+^CD20^+^/CD19^−^CD20^+^ cells were gated out of the CD3^−^CD56^−^ gate (8). Tregs were identified from the CD4^+^ population using CD127 and CD25 expression (CD127^hiCD25^hi) and CD39 and CD45RA were used to further classify these cells (9). CCR7, CD45RA, CD27, and CD28 allowed for further classification of the NKT-like cells (7). CD4^+^CD8^+^ CD4^+^CD8^+^ and CD4^+^CD8^−^ T cells were identified from the CD3^+^CD56^−^ gate (8). Tregs were identified using CD25 (IL-2Rα) and CD127 (IL-7Rα) markers without the inclusion of FoxP3, which requires intracellular staining. Previous studies have shown that CD25^hiCD127^lo/-CD4^+^ T cells are a good correlate of Tregs (54,55), although this strategy may over- or underestimate their frequency. It has been reported that Tregs can be further subsetted based on CD39 expression (7,56,57) and that CD39^+^ Tregs might play a role in certain autoimmune diseases like multiple sclerosis (58).

CD27 and IgD were chosen for identification of naive (IgD^CD27^), marginal zone-like (IgD^CD27^), and memory (IgD^CD27^) B cells as previously described (59). Marginal zone-like B cells can be further divided into IgM^+ marginal zone and IgD only memory B cells (8). When used in combination, CD24 and CD38 distinguish memory (CD24^hiCD38^neg), naive (CD24^intCD38^int), and transitional (CD24^intCD38^hi) B cells, and have been used for regulatory B cell identification (60,61). Plasmablasts can be identified based on expression of CD19, CD20, CD27, and CD38 (62). Memory B cells express increased levels of CXCR3 (72).

Chemokine receptors are important for the migration and positioning of immune cells (64). This panel includes CCR5, CCR6, CXCR3, and CXCR5. CCR5 is expressed by activated and memory T cells (65), γδ T cells (66), and Tregs (67). On human T cells, CCR6 is attributed to a Th17 (RORIγT) phenotype (68). On B cells, CCR6 expression is restricted to functionally mature cells capable of responding to antigen challenge (69). CXCR3 has been reported to be necessary for T cell clustering around antigen presenting cells and T cell bystander activation (70) and also to be expressed on subsets of γδ T cells (66). CXCR5 interacts with CXCL13, which promotes T cell trafficking to B cell follicles and germinal centers. These are crucial sites for the generation of high-affinity antibody responses (71). Moreover, it has been shown that chronic inflammation leads to modulation of chemokine receptor expression on peripheral blood B cells. In patients with rheumatoid arthritis, B cells show decreased expression of CXCR5 and CCR6 and increased levels of CXCR3 (72).

Monocyte subsets were identified using CD14 (lipopolysaccharide binding protein) and CD16 (FcγRIII). These two markers allow the identification of classical monocytes.
(CD14\(^+\)CD16\(^-\)), non-classical monocytes (CD14\(^+\)CD16\(^+\)), and an intermediate monocyte population (CD14\(^+\)CD16\(^-\)) (73). Intermediate monocytes expand in the presence of cytokines and inflammation. Non-classical monocytes have also been shown to expand in inflammatory diseases. It has been demonstrated that, over the course of infection, there is first an increase in intermediate monocytes followed by an increase in non-classical monocytes (74).

Table 2. Reagents used for OMIP-069

<table>
<thead>
<tr>
<th>SPECIFICITY</th>
<th>FLUOROCHROME</th>
<th>CLONE</th>
<th>PURPOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viability</td>
<td>Live Dead UV Blue</td>
<td>—</td>
<td>Viability</td>
</tr>
<tr>
<td>CD45</td>
<td>PerCP</td>
<td>HI30</td>
<td>Leukocytes</td>
</tr>
<tr>
<td>CD3</td>
<td>BV510</td>
<td>SK7</td>
<td>Pan T cell, NKT-Like cells</td>
</tr>
<tr>
<td>CD4</td>
<td>cFluor YG584</td>
<td>SK3</td>
<td>CD4 T and NKT-Like cells</td>
</tr>
<tr>
<td>CD8</td>
<td>BUV805</td>
<td>SK1</td>
<td>CD8 T, NK, and NKT-Like cells</td>
</tr>
<tr>
<td>CD25</td>
<td>PE-Alexa Fluor700</td>
<td>CD25-3G10</td>
<td>Regulatory T cells</td>
</tr>
<tr>
<td>TCRγδ</td>
<td>PerCP-eFluor 710</td>
<td>B1.1</td>
<td>Pan γδ T cell</td>
</tr>
<tr>
<td>CD14</td>
<td>Spark Blue 550</td>
<td>63D3</td>
<td>Monocyte differentiation</td>
</tr>
<tr>
<td>CD16</td>
<td>BUV496</td>
<td>3G8</td>
<td>Monocyte, NK cell, and dendritic cell differentiation</td>
</tr>
<tr>
<td>CD11c</td>
<td>eFluor 450</td>
<td>3.9</td>
<td>Dendritic Cell differentiation</td>
</tr>
<tr>
<td>CD19</td>
<td>Spark NIR 685</td>
<td>HIB19</td>
<td>B cells</td>
</tr>
<tr>
<td>CD20</td>
<td>Pacific Orange</td>
<td>HI47</td>
<td>B cells</td>
</tr>
<tr>
<td>CD24</td>
<td>PE-Alexa Fluor610</td>
<td>SN3</td>
<td>B cell differentiation</td>
</tr>
<tr>
<td>CD39</td>
<td>BUV661</td>
<td>TU66</td>
<td>B cell, T(_{reg}), and monocyte differentiation</td>
</tr>
<tr>
<td>IgD</td>
<td>BV480</td>
<td>IA6-2</td>
<td>B cell differentiation</td>
</tr>
<tr>
<td>IgG</td>
<td>BV605</td>
<td>G18-145</td>
<td>B cell differentiation</td>
</tr>
<tr>
<td>IgM</td>
<td>BV570</td>
<td>MHM-88</td>
<td>B cell differentiation</td>
</tr>
<tr>
<td>CD141</td>
<td>BB515</td>
<td>1A4</td>
<td>Dendritic cell differentiation</td>
</tr>
<tr>
<td>CD1c</td>
<td>Alexa Fluor 647</td>
<td>LI61</td>
<td>Dendritic cells, NKT-Like cells</td>
</tr>
<tr>
<td>CD123</td>
<td>Super Bright 436</td>
<td>6H6</td>
<td>Plasmacytoid dendritic cells</td>
</tr>
<tr>
<td>CD2</td>
<td>PerCP-Cy5.5</td>
<td>TS1/8</td>
<td>NK cell differentiation</td>
</tr>
<tr>
<td>CD56</td>
<td>BUV737</td>
<td>NCAM16.2</td>
<td>Pan NK cell, γδ T cell activation</td>
</tr>
<tr>
<td>CCR7</td>
<td>BV421</td>
<td>G043H7</td>
<td>T cell differentiation</td>
</tr>
<tr>
<td>CD27</td>
<td>APC-H7</td>
<td>M-T271</td>
<td>T and B cell differentiation</td>
</tr>
<tr>
<td>CD28</td>
<td>BV650</td>
<td>CD28.2</td>
<td>T cell and NK cell differentiation</td>
</tr>
<tr>
<td>CD45RA</td>
<td>BUV395</td>
<td>5F9</td>
<td>T cell and dendritic cell differentiation</td>
</tr>
<tr>
<td>CD95</td>
<td>PE-Cy5</td>
<td>DX2</td>
<td>T cell and B cell differentiation</td>
</tr>
<tr>
<td>CD127</td>
<td>APC-R700</td>
<td>HIL-7R-M21</td>
<td>Cytokine receptor; T cell differentiation</td>
</tr>
<tr>
<td>CD337</td>
<td>PE-Dazzle594</td>
<td>P30-15</td>
<td>NK cell differentiation</td>
</tr>
<tr>
<td>CCR6</td>
<td>BV711</td>
<td>G034E3</td>
<td>Chemokine receptor; T cell and B cell differentiation</td>
</tr>
<tr>
<td>CCR5</td>
<td>BUV563</td>
<td>2D7/CCR5</td>
<td>Chemokine receptor; Monocyte, dendritic cell, T cell, and B cell differentiation</td>
</tr>
<tr>
<td>CXCR5</td>
<td>BV750</td>
<td>RF882</td>
<td>Chemokine receptor; T cell differentiation</td>
</tr>
<tr>
<td>CXCR3</td>
<td>PE-Cy7</td>
<td>G025H7</td>
<td>Chemokine receptor; Dendritic cell, T cell, and B cell differentiation</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>PE-Fire810</td>
<td>L243</td>
<td>T cell and monocyte activation, NK cell lineage discrimination, dendritic cell lineage marker</td>
</tr>
<tr>
<td>CD38</td>
<td>APC-Fire810</td>
<td>HIT2</td>
<td>Monocyte, dendritic cell, T cell, and B cell activation/differentiation</td>
</tr>
<tr>
<td>CD57</td>
<td>FITC</td>
<td>HNK-1</td>
<td>NK and CD8(^+) T cell immune senescence</td>
</tr>
<tr>
<td>PD-1</td>
<td>BV785</td>
<td>EH12.2H7</td>
<td>T cell inhibitory receptor</td>
</tr>
<tr>
<td>CD159a</td>
<td>APC</td>
<td>REA110</td>
<td>NK, NKT-Like, and γδ T cell activation/differentiation</td>
</tr>
<tr>
<td>CD159c</td>
<td>PE</td>
<td>REA205</td>
<td>NK cell differentiation</td>
</tr>
<tr>
<td>CD314</td>
<td>BUV615</td>
<td>1D11</td>
<td>NK cell differentiation</td>
</tr>
</tbody>
</table>
With the markers present in this panel, basophils were identified as CD45dimCD123HLA-DR− (75). The phenotype of these cells can then be further characterized by evaluating expression of CD38, CD95, and CD25.

Total ILCs were identified using a similar strategy as presented in OMIP-055 (76). This subset was identified as CD45−CD127−Lin−. For lineage markers, we used CD14, CD19, CD20, and CD3. However, to fully identify these cells other markers should be excluded like CD1a, CD34, CD303, and FcγR1a. Despite lacking these markers, the cells identified as ILCs could be further classified based on expression of CD2, CD4, CCR6, CXCR3, CD27, CD28, CXCR5, and CCR7 as previously reported (77).

Finally, to identify the main dendritic cell subsets, CD11c, HLA-DR, CD141 (BDCA-3), CD1c (BDCA-1), and CD123 were used as previously described (9). pDCs were identified as lineage negative (CD3−CD19−CD56−CD14−) HLA-DR+CD123+ cells; conventional DCs were identified as CD123−CD11c+HLA-DR+, and they were further subset based on CD141 (78) and CD1c expression (79).

The manual gating strategy used to identify the main cell subsets, based on the descriptions provided above, is shown in Figure 1A. As it is more likely that a complex data set such as this would be analyzed using a pipeline containing both dimensionality reduction and clustering algorithms, we present in Figure 1B the computationally derived analogs of manually gated canonical subsets using such an unsupervised approach. When preparing for any kind of automated analysis, it is imperative that the data be of the highest quality, as any undesirable events or processing artifacts will negatively affect the downstream results. In this case, the scaling of the data was first checked to ensure the arcsinh transformation was unimodal around 0 and then the data were cleaned by manual gating to remove doublets, debris, and dead cells. The data were then run through flowCut (80) to check for aberrant signal patterns or events, and with none found. UMAP (81) was run to group phenotypically similar events into “islands” to illustrate differences both between and inside each population. FlowSOM (82) was subsequently used to cluster the events based on UMAP parameters and selected surface markers in order to emphasize differences between hard to resolve populations and then the resulting clusters were overlaid on the initial UMAP parameters. A traditional clustered heatmap analysis then followed to aid in the identification and labeling of the FlowSOM clusters (See Supporting Information Fig. S11A).

This 40-color panel (Table 2) presents a powerful tool for in-depth characterization of lymphocytes, monocytes, and dendritic cells present in human peripheral blood. It covers almost the entire cellular composition of the human peripheral immune system and will be particularly useful for studies in which sample availability is limited or unique biomarker signatures are sought. Taking advantage of full spectrum cytometry, we present a panel that highlights the first published OMIP to go beyond 28-color fluorescence flow cytometry with excellent population resolution.

**SIMILARITY TO PUBLISHED OMIPS**

This panel is similar to OMIPs -015, -023, -024, -030, -033, -034, -042, -50, -058, -063, which are all aimed at identifying the main leukocyte subsets in human blood. It partially overlaps with OMIPs -013, -017, -021, -030, and -060 for characterization of T cells; OMIPs -004, -006, and -015 for Treg immunophenotyping; OMIP -044 for dendritic cells; OMIPs -003, -033, and -051 for B cells; and OMIPs -029, and -039 for NK cells (6-11,22,29,44,45,55,83-96).

**STATEMENT OF ETHICAL USE OF HUMAN SAMPLES**

All human PBMCs used in this study were obtained from AllCells Alameda. Ethical review and regulatory compliance were conducted by Alpha Independent Review Board under Protocol number: 7000-SOP-045 (effective through April 26, 2021).

**ACKNOWLEDGMENTS**

The authors would like to thank BioLegend® for kindly providing the custom HLA-DR PE-Fire810 and CD38 APC-Fire810 (now commercially available). In addition, the authors would like to thank Janelle Shook and James Wei for their assistance with the manuscript and figure preparation, Geoff Kraker for doing the unsupervised analysis of the data, Patrick Duncker for critical reading of the manuscript, and Huimin Gu for her extensive work at testing different fluorochrome combinations in preparation for this panel development.

**AUTHOR CONTRIBUTIONS**

Lily M. Park: Conceptualization; data curation; formal analysis; methodology; validation; visualization. Joanne Lannigan: Data curation; formal analysis; project administration; resources; visualization; writing - original draft; writing - review and editing. Maria C. Jaimes: Conceptualization; data curation; formal analysis; methodology; project administration; resources; software; supervision; validation; visualization; writing - original draft; writing - review and editing.

**CONFLICT OF INTEREST**

Lily Park and Maria C. Jaimes are employees of Cytek Biosciences, Inc., the manufacturer of the Aurora full spectrum flow cytometer used in these studies. Joanne Lannigan is a paid consultant for Cytek Biosciences, Inc.

**LITERATURE CITED**


67. Lim HW, Broxmeyer HE, Kim CH. Regulation of traf.


72. Henneken M, Dorner T, Burmester GR, Berek C. Differential expression of che.

73. Gennari S, Riccarda Manser A, Weinhold S, Scherenschlich N, Uhrberg M.


Supplementary Material


Lily M. Park\textsuperscript{1}, Joanne Lannigan\textsuperscript{2}, and Maria C. Jaimes\textsuperscript{3}

\textsuperscript{1}Research and Development, Cytek Biosciences, Inc., Fremont, California, 94538-6407
\textsuperscript{2}Flow Cytometry Support Services, LLC, Alexandria, Virginia, 22314
\textsuperscript{3}Research and Development, Cytek Biosciences, Inc., Fremont, California, 94538-6407
INSTRUMENT CONFIGURATION AND INSTRUMENT SETUP OPTIMIZATION

This panel was developed on a Cytek® Aurora (Cytek Biosciences, Fremont, California) equipped with 5 lasers (355, 405, 488, 561, 640 nm) and 64 detectors. In this instrument, the optical design is such that the lasers are spatially separated with independent optical paths. The detection modules consist of avalanche photodiodes (APDs) coupled with narrow bandpass filters ranging from just above the laser wavelength up to 830 nm (Supplemental Figure 1). The number of detectors per laser module and bandwidth of the filters is detailed in Supplemental Table 1.

To determine optimal instrument/APD setup, the following approach was taken:

- A comprehensive set of commercially available fluorochromes was identified, making sure to cover as many possible peak emission wavelengths as possible across all 5 lasers.
- Gains were set such that each fluorochrome’s peak emission channel corresponds to their maximum emission wavelength, and the spectral patterns did not exhibit any steep changes from one channel to the next.
- PBMCs stained with anti-CD4 labeled with each fluorochrome were acquired at a gain of 50 for each detector across all lasers (range on the Cytek Aurora is from 1 to 3000) and then at 2-fold increments, until the stain index was stable. If, at gain 50, the stain index was already maximal, 2-fold decrease gains were tested. Stain index was calculated using peak channel statistics. The following formula was used:

\[
\text{Stain Index} = \frac{\text{MFI}_{\text{positive population}} - \text{MFI}_{\text{negative population}}}{2 \times \text{rSD}_{\text{negative population}}}
\]

- Gains were then set for optimal stain index in the peak emission channel. If no fluorochrome peaked in a given channel, the gain was adjusted based on an adjacent emitting fluorochrome, so that the signal did not exceed the signal from the peak detector and a smooth transition to the peak channel was maintained.
- To accommodate brighter signals (due to antigens with higher expression level, differences in expression level across donors, or up-regulation of receptors), PBMCs stained with anti-CD8 labeled with each fluorochrome were acquired at the optimal gains established in the previous step and signals verified to be on scale (< 2x10^6 on a full scale of 4x10^6). If needed, gains were adjusted proportionately across the detectors to put the brightest signals on scale.
- To identify gains which had the least impact on spillover spread, we compared spread values based on the Spillover Spreading Matrix (SSM) at different gains; using the gains established in the previous step, and with a 2- and 4-fold increase, to ensure the lower gains minimized spread values.
- The final gain settings were saved in the SpectroFlo® software as CytekAssaySetting. These settings are automatically updated during daily QC based on calibrated bead MFI targets to ensure consistent setup across days.

Supplemental Figure 1. Schematic of Optical Layout for 5 Laser Aurora
The Cytek Aurora used to develop the panel was equipped with 5 lasers. The optical paths for each of the 5 lasers (UV 355 nm, Violet 405 nm, Blue 488 nm, Yellow Green 561 nm, and Red 640 nm) are represented. The lasers are spatially separated, each has an independent optical path, and through optical fibers light is directed to individual detector modules using avalanche photodiodes (APD) as photodetectors.
### Supplemental Table 1. Detector Modules Configuration for 5 Laser Aurora

The detectors and wavelength information of the bandpass filters associated with each laser detector are listed. UV laser detector module: 16 detectors (UV1-UV16); violet laser detector module: 16 detectors (V1-V16); blue detector module: 14 detectors (B1-B14); yellow green laser detector module: 10 detectors (YG1-YG10); red laser detector module: 8 detectors (R1-R8). Wavelengths of the filters are continuous, except for wavelengths associated with the laser line emissions (UV2-UV3, UV6-UV7, UV8-UV9, UV10-UV11, V4-V5, V7-V8, V10-V11, B3-B4, B6-B7, YG3-YG4).

<table>
<thead>
<tr>
<th>UV (355 nm - 20 mW)</th>
<th>Violet (405 nm - 100 mW)</th>
<th>Blue (488 nm - 50 mW)</th>
<th>Yellow Green (561 nm - 50 mW)</th>
<th>Red (640 nm - 80 mW)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Detector</td>
<td>Center Wavelength</td>
<td>Bandwidth</td>
<td>Detector</td>
<td>Center Wavelength</td>
</tr>
<tr>
<td>1</td>
<td>372.5</td>
<td>15</td>
<td>1</td>
<td>427.5</td>
</tr>
<tr>
<td>2</td>
<td>387.5</td>
<td>15</td>
<td>2</td>
<td>443</td>
</tr>
<tr>
<td>3</td>
<td>427.5</td>
<td>15</td>
<td>3</td>
<td>458</td>
</tr>
<tr>
<td>4</td>
<td>443</td>
<td>15</td>
<td>4</td>
<td>473</td>
</tr>
<tr>
<td>5</td>
<td>458</td>
<td>15</td>
<td>5</td>
<td>508</td>
</tr>
<tr>
<td>6</td>
<td>473</td>
<td>15</td>
<td>6</td>
<td>524.5</td>
</tr>
<tr>
<td>7</td>
<td>514</td>
<td>28</td>
<td>7</td>
<td>541.5</td>
</tr>
<tr>
<td>8</td>
<td>542</td>
<td>28</td>
<td>8</td>
<td>580.5</td>
</tr>
<tr>
<td>9</td>
<td>581.5</td>
<td>31</td>
<td>9</td>
<td>598</td>
</tr>
<tr>
<td>10</td>
<td>612.5</td>
<td>31</td>
<td>10</td>
<td>615</td>
</tr>
<tr>
<td>11</td>
<td>664</td>
<td>27</td>
<td>11</td>
<td>664</td>
</tr>
<tr>
<td>12</td>
<td>691.5</td>
<td>28</td>
<td>12</td>
<td>691.5</td>
</tr>
<tr>
<td>13</td>
<td>720</td>
<td>29</td>
<td>13</td>
<td>720</td>
</tr>
<tr>
<td>14</td>
<td>749.5</td>
<td>30</td>
<td>14</td>
<td>749.5</td>
</tr>
<tr>
<td>15</td>
<td>779.5</td>
<td>30</td>
<td>15</td>
<td>779.5</td>
</tr>
<tr>
<td>16</td>
<td>811.5</td>
<td>34</td>
<td>16</td>
<td>811.5</td>
</tr>
</tbody>
</table>
STRATEGY FOR FLUOROCHROME SELECTION AND FLUOROCHROME CHARACTERIZATION

The first step for the panel development consisted of identifying the best possible 40 fluorochrome combination. The following criteria were applied for this selection:

- **Unique spectra**: The spectra of over 65 commercially available fluorochromes were analyzed. Fluorochromes with peak emissions occurring in different channels were identified, as well as fluorochromes that, despite sharing the same peak emission, have a different spectrum. Next, the fluorochrome signature uniqueness, determined by comparing the full spectrum across all 64 detectors, was quantified using an index developed by Cytek Biosciences, and available through the SpectroFlo software, called Similarity Index. This index uses the cosine of the angle between the vectors defined for each fluorochrome in a 64-dimensional space to compare two signatures. This index ranges from 0 to 1; 0 indicating the 2 fluorochromes do not share any spectral characteristics, and 1 indicating that the spectra are identical. Based on testing of multiple fluorochrome combinations, it was determined that similarity indices of 0.98 or less indicated that fluorochromes were different enough to be used together.

- **Overall fluorochrome combination compatibility**: This assessment was guided by a Cytek developed metric, also available in the SpectroFlo software, called the Complexity Index. This index measures the interference among a specific combination of fluorochromes and predicts the impact on the autofluorescence distribution of the spectrally unmixed results while also considering spillover (1,2). The lower the complexity index, the higher the probability that the fluorochrome combination will work together and yield high resolution data through reduced spread. Similarity Index and Complexity Index together provide a measure of the degree of overall interferences due to spillover between and among fluorochromes. Note: Similarity and Complexity Indices are currently under patent application. Once issued, formulas will be made publicly available.

Based on the above criteria, 40 fluorochromes were selected (Supplemental Figures 2A and 2B), minimizing fluorochrome pairs with very high similarity indices and providing the lowest complexity index (complexity index=54). The distribution of the selected fluorochromes across lasers and emission wavelengths is presented in Supplemental Table 2. The pairs with the highest similarity indices, and hence higher predicted spread between them, were BB515 and FITC (0.98), BV421 and Super Bright 436 (0.97), Super Bright 436 and eFluor 450 (0.94), and Alexa Fluor 647 and Spark NIR 685 (0.92). Additionally, an effort was made to minimize the use of custom reagents. Out of the 40 fluorochromes used in this panel, only one is custom, and is commercially available through BioLegend® (San Diego, CA): PE-Fire 810. This fluorochrome was selected to take advantage of the high detection efficiency that APDs have in the far-red range of emission.

Next, the selected 40 fluorochromes were ranked for brightness using anti-CD4 single stained cells available for 38 of the fluorochromes, and using HLA-DR PE-Fire 810 and CD38 APC-Fire 810 (Supplemental Figure 2C). Finally, spread was assessed by calculating the SSM using FlowJo™ version 10.6.2 with the same data used to rank fluorochrome brightness (Supplemental Figure 2D). As expected, based on the spectrum and similarity indices, the pairs with the highest SSM values were BB515 into FITC (SSM=29) and FITC into BB515 (SSM=23). Other combinations showing high spread were APC into Alexa Fluor 647 (SSM=14.2), Spark Blue 550 into FITC (SSM=13.2), BUV661 into APC (SSM=11.7), and BV480 into BV510 (SSM=11.45). Of the 1,560 combinations of fluorochromes, only 13 had an SSM greater than 10, with the majority (91%) having SSM values of 4 or less. Differences of 10-fold in the SSM are equivalent to approximately a log greater spread in the data (3).

PANEL DESIGN STRATEGY

Basic principles for best practices for panel design based on previously published approaches used for conventional cytometry were followed (4). Antigens were classified as primary, secondary, and tertiary based on level of expression, and co-expression was assessed using a schematic gating tree and researching the expression for each marker on the subsets of interest. Next, fluorochrome assignment was made following these steps:

**Step 1: Assignment of Fluorochromes with Limited Conjugate Availability**

In order to minimize the use of custom reagents, there were limitations on the fluorochrome assignment for certain markers:

- HLA-DR PE-Fire 810, a custom reagent, was readily available through BioLegend® and fit into the panel.
- CD38 APC-Fire 810 was originally a custom conjugate but is now commercially available (Supplemental Table 4).
Stain Index

Pacific Orange, PerCP, LIVE/DEAD Blue, BV495, BV510, BV570, PE-Alexa Fluor 610, APC-Fire 810, eFluor 450, Spark NIR 685, FITC, BV563, APC-H7, BV605, BUV615, PE-Alexa Fluor 700, PerCP-eFluor 710, BV737, BV750, BV771, BB515, PE-Alexa Fluor 700, PerCP-eFluor 700, BV615, BV785, BV480, Spark Blue 550, Super Bright 436, PE-Fire 810, PE-Alexa Fluor 610, PerCP-Cy5.5, BV570, BV510, BV495, FITC, LIVE/DEAD Blue, PerCP, BUV661, BUV563, BUV615, APC, BV421, APC-Dazzle 594, Alexa Fluor 647, PE-CY5, PE-CY7, PE.
OMIP-069: 40 Color Deep Immune Profiling

cells labeled with the indicated fluorochromes, except for PE-Fire 810 (HLA-DR) and APC-Fire 810 (CD38).

displayed.

At the bottom of the matrix, the complexity index (blue arrow), a metric to evaluate the complexity of the entire combination of fluorochromes, is displayed. (C) Spillover indices calculated for each of the fluorochromes in the panel, ranked from low to high. Spillover indices were calculated using CD4 stained cells labeled with the indicated fluorochromes, except for PE-Fire 810 (HLA-DR) and APC-Fire 810 (CD38). (D) SSM calculated for all fluorochromes in the panel.

Spillover Spreading Matrix Color Coding:

value of "1" indicates there is virtually no difference between 2 fluorochromes, while a value of "0" indicates two fluorochromes are completely unique. The chart displays the numerical value for each pair of fluorochromes identified for use in the OMIP-069 panel. Based on the testing of multiple fluorochrome combinations (data not shown), it was determined that any fluorochrome pair having a similarity index of 0.98 or lower could be accurately unmixed with appropriate single stained controls. Supplemental Figure 2. Fluorochrome Selection Evaluations

A series of evaluations were conducted to identify the best combination of 40 fluorochromes that would provide unique optical spectral signatures, appropriate signal intensities, and minimal spread into neighboring channels. (A) Spectral signatures of 40 fluorochromes visualized using the Cytel Spectrum Viewer. All signatures were normalized to peak channels for direct comparison. (B) Results of the Similarity Index Matrix (SIM) which measures how similar two spectra are to each other.

Supplemental Figure 2. Fluorochrome Selection Evaluations

A series of evaluations were conducted to identify the best combination of 40 fluorochromes that would provide unique optical spectral signatures, appropriate signal intensities, and minimal spread into neighboring channels. (A) Spectral signatures of 40 fluorochromes visualized using the Cytel Spectrum Viewer. All signatures were normalized to peak channels for direct comparison. (B) Results of the Similarity Index Matrix (SIM) which measures how similar two spectra are to each other.
<table>
<thead>
<tr>
<th>Approx. Emission Wavelength (nm)</th>
<th>UV</th>
<th>Violet</th>
<th>Blue</th>
<th>Yellow Green</th>
<th>Red</th>
</tr>
</thead>
<tbody>
<tr>
<td>395</td>
<td>BUV395</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>420</td>
<td></td>
<td>BV421</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>440</td>
<td></td>
<td></td>
<td>Super Bright 436</td>
<td></td>
<td></td>
</tr>
<tr>
<td>450</td>
<td></td>
<td></td>
<td></td>
<td>eFluor 450</td>
<td></td>
</tr>
<tr>
<td>480</td>
<td></td>
<td></td>
<td>BV480</td>
<td></td>
<td></td>
</tr>
<tr>
<td>500</td>
<td>BUV496</td>
<td></td>
<td></td>
<td>BB515</td>
<td></td>
</tr>
<tr>
<td>520</td>
<td></td>
<td>BV510</td>
<td></td>
<td>FITC</td>
<td></td>
</tr>
<tr>
<td>550</td>
<td></td>
<td>Pacific Orange</td>
<td></td>
<td>Spark Blue 550</td>
<td></td>
</tr>
<tr>
<td>570</td>
<td>BUV563</td>
<td>BV570/Pacific Orange</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>580</td>
<td></td>
<td></td>
<td></td>
<td>cFluor YG584/PE</td>
<td></td>
</tr>
<tr>
<td>600</td>
<td>BUV615</td>
<td>BV605</td>
<td></td>
<td>PE-Dazzle 594</td>
<td></td>
</tr>
<tr>
<td>660</td>
<td>BUV661</td>
<td>BV650</td>
<td></td>
<td>PE-Alexa Fluor 610</td>
<td>APC</td>
</tr>
<tr>
<td>680</td>
<td></td>
<td></td>
<td>PerCP</td>
<td>PE-Cy5</td>
<td>Alexa Fluor 647</td>
</tr>
<tr>
<td>690</td>
<td></td>
<td></td>
<td>PerCP-Cy5.5</td>
<td>Spark NIR 685</td>
<td></td>
</tr>
<tr>
<td>700</td>
<td></td>
<td></td>
<td>BV711</td>
<td>PerCP-eFluor 710</td>
<td>PE-Alexa Fluor 700</td>
</tr>
<tr>
<td>730</td>
<td>BUV737</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>750</td>
<td></td>
<td>BV750</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>780</td>
<td></td>
<td>BV785</td>
<td></td>
<td>PE-Cy7</td>
<td>APC-H7</td>
</tr>
<tr>
<td>800</td>
<td>BUV805</td>
<td></td>
<td></td>
<td>PE-Fire 810</td>
<td>APC-Fire 810</td>
</tr>
</tbody>
</table>

**Supplemental Table 2. Fluorochrome Optical Layout**

Fluorochromes intended for use in the OMIP-069 panel are presented by primary laser excitation (columns) and approximate emission wavelengths of the peak detector (rows). Fluorochromes which peaked in the same detector (cFluor YG584 and PE; BV570 and Pacific Orange) are shown as sharing the same emission block. This table layout provided the information regarding potential sources of spread and helped to inform the assignment of markers to fluorochromes to minimize any loss of population resolution.
• CD4 was the only reagent commercially available in cFluor YG584.
• There were limited choices for PE-Alexa Fluor 700, of which CD25 was the only option based on the markers in the panel.
• There were limited choices for PE-Alexa Fluor 610, of which CD24 was the only option based on the markers in the panel.

**Step 2: Selection of Viability Dye**
LIVE/DEAD™ Fixable Blue (Thermo Fisher, Waltham, MA) was selected for assessing viability as it has a unique signature that does not interfere with the use of other UV excitable fluochromes.

**Step 3: Assignment of Fluorochromes Based on Primary Antigen Classification and Co-Expression**
Dimmest fluorochromes were assigned to antigens expressed at high levels and with high level of co-expression with other markers in the panel, while also minimizing spread:
- CD45 in PerCP, co-expressed with all markers in the panel
- CD20 in Pacific Orange, co-expressed with all B cell makers
- CD45RA in BUV395, co-expressed with a high number of markers
- CD3 in BV510, co-expressed with all T cell markers
- CD16 in BUV496, co-expressed with all NK and monocyte markers
- CD2 in PerCP-Cy5.5, co-expressed with T cells and NK cell markers
- CD8 in BUV805, high antigen density

**Step 4: Assignment of Fluorochromes Based on Tertiary Antigen Classification**
Next, to maximize resolution, tertiary markers were assigned to bright fluorochromes, trying when possible to use fluorochromes whose signals were not severely impacted by spread from multiple fluorochromes. Moreover, information about clones/performance from previous panels developed and tested in the lab was used to make these selections:
- CD123 in Super Bright 436, used successfully in previous panels
- CD1c in Alexa Fluor 647, per OMIP-044
- CD141 in BB515
- TCRγδ in PerCP-eFluor 710, used successfully in previous panels
- CD159a in APC, desired clone from OMIP-039 with limited availability, no co-expression or loss of resolution with CD1c Alexa Fluor 647
- CD159c in PE, desired clone from OMIP-039 with limited availability, no co-expression or loss of resolution with CD4 cFluor YG584
- PD-1, originally tested in BV650, in BV785 with improved resolution (data not shown)
- CXCR3 and CXCR5 in PE-Cy7 and BV750, respectively, both used successfully in previous panels

**Step 5: Assignment of Fluorochromes for Remaining Markers**
Finally, for the remaining markers (mainly secondary antigen markers), it was important to take into consideration possible sources of spread that could impact resolution utilizing [Supplemental Table 2](#) and assign markers so that the following two conditions were met:
- Regarding fluorochromes in columns (indicating primary excitation laser): avoid highly expressed antigens being placed in cells adjacent to co-expressed antigens with lower expression.
- Regarding fluorochromes in rows (indicating similar emission wavelength): avoid highly expressed antigens being placed in cells on the same row as co-expressed markers with lower expression.

Beginning with assignments within the same column/primary laser excitation:
- CD56 in BUV737, previous experience indicated no impact on CD8 BUV805 resolution
- CCR7 in BV421, no co-expression or loss of resolution with CD123 Super Bright 436
- IgD in BV480, no co-expression or loss of resolution with CD3 BV510
- CD11c in eFluor 450, high level of expression, no co-expression or loss of resolution with CD123 Super Bright 436 or IgD BV480
- IgM in BV570 and IgG to BV605, mutually exclusive expression and resolution not impacted by CD20 Pacific Orange
- CD57 in FITC, used in previous panels, no co-expression or loss of resolution with CD141 BB515
- CD14 in Spark Blue 550, no co-expression with CD57 FITC and testing showed no loss of resolution
- CD337 in PE-Dazzle 594, no co-expression or loss of resolution with CD4 cFluor YG584 or CD24 PE-Alexa
Fluor 610
• CD19 in Spark NIR 685, limited reagent availability, no co-expression or loss of resolution with CD1c Alexa Fluor 647
• CD127 in APC-R700, used in previous panels, no co-expression or loss of resolution with CD19 Spark NIR 685. Of note, CD127 clone A019D5 was originally tested in APC-Fire 750, but severe loss of signal was observed in the multicolor tube. We then switched to clone HIL-7R-M21 and tested in parallel BUV737 and APC-R700, and consistent results were only achieved with the APC-R700 conjugate and hence this reagent was selected.

Next steps focused on the remaining assignments per row/emission wavelength:
• CD16 in BUV496, used in previous panels with good resolution and no co-expression or loss of resolution with CD141 BB515
• CCR5 in BUV563, low level of expression mitigated spread into CD4 cFluor YG584
• CD314 in BUV615, low level of expression mitigated spread into CD337 PE-Dazzle 594
• CD39 in BUV661, low level of expression, and no co-expression with CD1c, mitigated spread into Alexa Fluor 647
• CD28 in BV650, no co-expression or loss of resolution with CD159a APC
• CD95 in PE-Cy5, used in previous panels with good resolution and no co-expression or loss of resolution with CD1c Alexa Fluor 647 or CD159a APC
• CCR6 in BV711, low level of expression mitigated spread into other ~700 nm emitting fluorochromes
• CD27 in APC-H7, used in previous panels with good resolution and no spread into other fluorochromes

The distribution of the final panel of reagents across lasers and emission wavelengths is presented in Supplemental Table 3.

PANEL TESTING
Once the theoretical panel design was finalized, testing of the panel included the following steps:

Step 1: Antibody Titration
All reagents were titrated using frozen PBMCs, at an average of 100,000 cells per test. The cells were resuspended in a final volume of 200 μl of staining buffer (BD Stain Buffer) to mimic the final staining volume of the multicolor (MC) tube. The antibodies that came bottled for use at 5 μl/test were tested in 2-fold serial dilutions ranging from 10 μl to 0.15 μl per test, and the antibodies that came bottled at a concentration in μg/ml were tested from 1 μg (1000 ng) to 15 ng per test. In both cases, titers were reported in nanograms (ng) per test (Supplemental Figure 3). Note that the selected titer was not necessarily the optimal titer (higher stain index) in the single stained titration. This was a result of performance comparison of the single stain (SS) to the MC samples, see step 4 below (Supplemental Figure 6B).

Step 2: Reference Control Optimization (Supplemental Figure 4)
As for compensation, the unmixing accuracy is highly dependent on the quality of the reference controls and their ability to accurately represent the spectra of fluorochromes present in the MC staining. Using a full spectrum flow cytometer allows detection of even the smallest differences in fluorochrome emission. It is a well known phenomena that fluorochrome antibodies bound to beads vs. cells can produce slight differences in the spectra that are emitted (7). To determine which reference control materials could be used to produce identical spectra for the fully stained sample, both beads and cells were tested. For this purpose, beads and cells stained with exactly the same reagents included in the panel were tested in parallel. Unmixing accuracy using beads as controls was tested by evaluating the unmixing results of the SS cells. For some of the markers/fluorochromes, the use of a bead reference control led to unmixing inaccuracies. Errors were identified with the following fluorochromes: BUV496, BUV563, BUV661, BUV805, BV480, BV570, Spark Blue 550, PE-Cy5, APC, and APC-Fire 750. See Supplemental Figure 4 for two examples where such an error occurred. In order to fully document why errors were observed, the normalized full spectrum of each of these dyes when the antibody was bound to the beads was compared to the normalized full spectrum of the same fluorochrome when the antibody was bound to cells. As expected, differences in the spectrum in specific wavelength regions fully correlated with the unmixing errors observed (Supplemental Figure 4). Beads could potentially be used for controls for all other fluorochromes. In the experiments run for this publication, cells were always used as controls and used to evaluate panel performance, see step 4 below.
Using the information from [Supplemental Table 2](#), assignment of fluorochromes to antigens were based on 1) reagent fluorochrome availability, 2) whether an antigen was classified as primary, secondary, and tertiary based on level of expression, and 3) co-expression assessed based on a schematic gating tree. Assignments were also made based on the following goals: 1) avoid highly expressed antigens being placed in adjacent cells in the same column (indicating primary excitation laser) as co-expressed antigens with lower expression; and 2) avoid highly expressed antigens being placed in cells on the same row (indicating similar emission wavelength) as co-expressed markers with lower expression.

**Supplemental Table 3. Fluorochrome and Reagent Optical Layout**

<table>
<thead>
<tr>
<th>Approx. Emission Wavelength (nm)</th>
<th>UV</th>
<th>Violet</th>
<th>Blue</th>
<th>Yellow Green</th>
<th>Red</th>
</tr>
</thead>
<tbody>
<tr>
<td>395</td>
<td>CD45RA BUV395</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>420</td>
<td>CCR7 BV421</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>440</td>
<td>CD123 Super Bright 436</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>450</td>
<td>Viability UV (L/D Blue)</td>
<td>CD11c eFluor 450</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>480</td>
<td>IgD BV480</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>500</td>
<td>CD16 BUV496</td>
<td>CD141 BB515</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>520</td>
<td>CD3 BV510</td>
<td>CD57 FITC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>550</td>
<td>CD14 Spark Blue 550</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>570</td>
<td>CCR5 BUV563</td>
<td>IgM BV570/CD20 Pacific Orange</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>580</td>
<td></td>
<td></td>
<td></td>
<td>CD4 cFluor YG584/CD159c PE</td>
<td></td>
</tr>
<tr>
<td>600</td>
<td>CD314 BUV615</td>
<td>IgG BV605</td>
<td>CD337 PE-Dazzle 594</td>
<td></td>
<td></td>
</tr>
<tr>
<td>660</td>
<td>CD39 BUV661</td>
<td>CD28 BV650</td>
<td>CD24 PE-Alexa Fluor 610</td>
<td>NKG2A APC</td>
<td></td>
</tr>
<tr>
<td>680</td>
<td>CD45 PerCP</td>
<td>CD95 PE-Cy5</td>
<td>CD1c Alexa Fluor 647</td>
<td></td>
<td></td>
</tr>
<tr>
<td>690</td>
<td>CD2 PerCP-Cy5.5</td>
<td>CD19 Spark NIR 685</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>700</td>
<td>CCR6 BV711</td>
<td>TCRγδ PerCP-eFluor 710</td>
<td>CD25 PE-Alexa Fluor 700</td>
<td>CD127 APC-R700</td>
<td></td>
</tr>
<tr>
<td>730</td>
<td>CD56 BUV737</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>750</td>
<td>CXCR5 BV750</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>780</td>
<td>PD-1 BV785</td>
<td>CXCR3 PE-Cy7</td>
<td>CD27 APC-H7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>800</td>
<td>CD8 BUV805</td>
<td>HLA-DR PE-Fire 810</td>
<td>CD38 APC-Fire 810</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Supplemental Figure 3. Antibody Reagent Titrations
Optimal concentrations of all antibodies were determined through titration experiments. Two-fold dilutions of antibodies were tested. For antibodies that came bottled for use at 5 μl/test, a range from 10 μl to 0.15 μl/test was tested, while concentrations from 1 μg to 15 ng/test was tested for antibodies that came bottled at a concentration in μg/ml. Files were concatenated for analysis using FCS Express version 7 (De Novo Software). Titrations for reagents primarily excited by the UV laser (355 nm) (A), violet laser (405 nm) (B), blue laser (488 nm) (C), yellow-green laser (561 nm) (D), and red laser (640 nm) (E) are shown. Final titration results are expressed as ng/test (see Supplemental Table 4).
Supplemental Figure 4. Examples of Unmixing Errors Using Beads vs. Cells as Reference Controls

In evaluating the unmixing outcome when using beads vs. cells as reference controls, several fluorochromes were identified for which the use of beads led to unmixing inaccuracies. These unmixing inaccuracies were the result of minor differences in the spectra of fluorochromes when the same antibody was bound to beads vs. cells. (A) When CD39 BUV661 bound beads were used to unmix CD39 BUV661 single stained cells, unmixing inaccuracies were observed in BUV395 (peak channel UV2) and APC (peak channel R1). The normalized overlay demonstrates where differences in the spectra were observed between the two reference control materials (beads vs. cells). The box in the upper right shows the normalized MFIs for the two channels where the differences are highlighted (colored circles and arrows).

(B) IgM BV570 bound beads, used to unmix IgM BV570 SS cells, resulted in inaccurate unmixing in BV421 (peak channel V1) and cFluor YG584 (peak channel YG1). The normalized overlay demonstrates where differences in the spectra were observed between the two reference control materials (beads vs. cells). The box in the upper right shows the normalized MFIs of the two channels where the differences are highlighted (colored circles and arrows).
Step 3: Unmixing Accuracy of the MC Tube
Data was unmixed using the SpectroFlo software v2.2 using an ordinary least squares algorithm. To check that the unmixing of the MC tube was accurate, data was cleaned up (singlets, live, scatter gate, aggregate exclusion if needed) and NxN plot permutations were screened (Supplemental Figure 5). For most of the markers, unmixing was very accurate (Supplemental Figure 5A). Errors were only visually identified in 16 of the 1560 combinations. An example of the errors that were encountered is presented in Supplemental Figure 5B. Corrections were applied only when the errors were observed between fluorochromes that had spillover between them and when the authors had solid knowledge of the expected expression pattern. The correction was estimated visually to align the median of the negative and positive populations in the y-dimension. The maximum correction that had to be applied was 2.8%, corresponding to BUV737 into BV750. Of note, these corrections did not have an impact on the outcome of the analysis, either manual or unsupervised.

Step 4: SS Control vs. MC Resolution for Each Marker (Supplemental Figure 6A-B)
After unmixing accuracy was checked, the resolution of every marker in the panel was checked by comparing the SS control tube to the same marker in the MC sample. Three different scenarios were observed:
1. Resolution was identical, and no action was needed.
2. The positive population in the MC tube was dimmer. In this case the titer was adjusted (Supplemental Figure 6B), and the staining protocol was evaluated for any possible staining optimization (see step 6 below and Supplemental Figure 9B).
3. The negative population in the MC tube was significantly wider, resulting in lower population resolution (lower stain index). In this case, data was gated according to the population gating hierarchy and evaluated for any compromise in resolving the population of interest. In all cases it was determined that the introduction of spread for a given marker did not negatively impact the overall performance of the panel.

Step 5: Assessment of Spread Impact on Resolution (Supplemental Figures 7 and 8)
One of the great advantages of full spectrum flow cytometry is the ability to utilize highly overlapping fluorochromes that traditionally could not be used together in conventional flow cytometers. This capability was critical for the development of a 40-color panel. However, highly overlapping fluorochromes are known to exhibit increased spread into other fluorochromes, which could impact resolution quality. For highly overlapping fluorochromes where significant spread was anticipated, visual inspection of those combinations and impact of the spread were evaluated (Supplemental Figure 7). In general, based on good panel design practices, these occurred in combinations of markers that are not co-expressed and therefore did not have a substantive negative impact.

FMO controls were used to guide and/or assess positive and negative delineations (Supplemental Figure 8A). FMOs were run for the following markers with low level of expression: CD25, CXCR5, CCR5, CCR6, and PD-1. For each of the main cellular subsets (monocytes, TCRγδ+, CD3+, CD4+, CD8+, CD3+CD56+, CD19+CD20+, and CD3-CD56+), gates to identify positive events for these markers were set based on the FMO control (lower row for each marker) and applied to the MC samples (upper row for each marker). For all the markers evaluated, identification of positive events was straightforward.

In addition, the impact of spread on population resolution was evaluated by comparing the MC samples with FMOs of the highly overlapping dye (Supplemental Figure 8B). FMOs for BB515, FITC, PE-Alexa Fluor 610, and Spark NIR 685 were run to assess the impact of spread introduced by these fluorochromes into fluorochromes with a high similarity. BB515 and FITC were chosen because these dyes had the highest values in the SSM matrix. PE-Alexa Fluor 610 and Spark NIR 685 were chosen because, prior to this panel, there was no experience using them in combination with PE-Dazzle 594 and Alexa Fluor 647, respectively. Plots on the left show the population resolution in the MC sample while plots on the right show the resolution of the same population in the indicated FMO control. When differences in spread of the negative population were observed, a bar measuring the spread was added to each plot to facilitate visual comparison. To assess the impact of spread from FITC into BB515, lineage negative (Lin-) cells were plotted by HLA-DR vs. CD141 to visualize the resolution of CD141+ dendritic cells (first row). For BB515 spread into FITC, cells were gated to evaluate CD57 resolution on NK cells (second row). The spread from PE-Alexa Fluor 610 into PE-Dazzle 594 was evaluated by observing the resolution of CD337 on NK cells (third row). Finally, to assess the spread introduced by Spark NIR 685 into Alexa Fluor 647, cells were gated on Lin- and HLA-DR vs CD1c plotted to represent the impact on resolution of CD1c+ dendritic cells (last row). This analysis demonstrated minimal spread impact on resolution.
Supplemental Figure 5. QC of Unmixing Accuracy of MC Stained Sample

For the MC samples, NxN plots were generated to visually assess the unmixing accuracy. Data plotted for evaluation was gated on singlets, scatter, live, and non-aggregates. (A) Two representative examples where unmixing was accurate are presented; CD39 BUV661 and IgM BV570. The plots presented are based on the data from Supplemental Figure 4. In each of the presented NxN plots, the same marker is plotted on the x-axis (CD39 BUV661 on the left and IgM BV570 on the right) and the y-axes represent every other fluorochrome in the panel. When unmixing was performed using SS cells as reference controls, no significant unmixing inaccuracies were observed. (B) Unmixing errors were observed in a minority of combinations (16 in the 40x40 matrix). A representative example of an error observed in the unmixing accuracy of CD56 BUV737 is presented (left panel, red box), namely into BV750 and BV785. Minimal corrections were required to align the negative and positive populations (right panel, red box): 2.8% into BV750 and -1% into BV785.
Supplemental Figure 6. Staining Resolution: SS vs. MC Samples
As part of the panel optimization, each marker in the MC stained samples was evaluated to determine whether an optimal resolution was maintained. To assess this, staining patterns were compared between the SS controls and the MC sample using PBMCs from the same donor. (A) For both SS (gray line) and MC (black line) samples, the data in the overlays were gated on singlets and, depending on the marker, lymphocyte or monocyte scatter gates. (B) In cases where this assessment identified reduced resolution in the MC samples for a given marker due to lower intensity of the positive signal (top row), antibody concentrations were increased by one titer point to get as close as possible to the resolution obtained in the SS tube (bottom row). Note that in those cases, doubling the titer in the MC tube increased the brightness of the positive population and had no impact on the negative population (no shifts were observed), resulting in increased resolution.
Supplemental Figure 7. Assessment of Highly Overlapping Fluorochromes

The impact of spread introduced by using highly overlapping fluorochromes was assessed using the MC sample. Fluorochrome combinations having the 16 highest values in the spillover spread matrix (SSM) (Supplemental Figure 2D) are presented. Plots are gated on singlets, live, non-aggregates, FSC/SSC low/intermediate, and CD45+. The fluorochrome on the x-axis introduces spread to the fluorochrome on the y-axis, except for the first plot (BB515 and FITC), as in this case both fluorochromes have a significant spread into each other. SSM values are presented in each plot. Note that the antigens assigned to the pairs with the highest SSM values (FITC and BB515, APC and Alexa Fluor 647, Spark Blue 550 and FITC) have no co-expression. The Similarity Index for each fluorochrome pair is indicated in the box in the upper right hand corner. The highly correlated distributions (diagonals) of the autofluorescent populations in the combinations that have high Similarity Indices is expected behavior for such highly overlapping dyes (2).

OMIP-069: 40 Color Deep Immune Profiling
Multicolor

FMO

CD25 PE-Alexa Fluor 700

Monocytes

TCRγδ

CD3+

CD4+

CD8+

T regs

CD3- CD56+

CD3- CD56+

CD3 CD56+

CXCR5 BV750

CCCR5 BUV563

CCR6 BV711

PD-1 BV785
Supplemental Figure 8. Fluorescence Minus One (FMO) Controls
FMOs were used as a quality control for two different purposes: to assess the accuracy in the gating/identification of populations where there was low level expression (A) or to assess the impact of spread in the resolution of a given marker/population (B). All the markers evaluated with FMOs show clear identification of positive events (A), while minimal spread of the negative populations were observed (black lines). Nearly identical population resolution was achieved with and without the highly overlapping fluorochrome present in the panel (blue bars) (B).
impact on the spread of the negative population and hence no loss of resolution resulting from the use of these highly overlapping dyes.

**Step 6: Fine Tuning of Staining Protocol (Supplemental Figure 9)**

Based on the results of the above assessments of the panel’s performance and other independent observations, several adjustments to the staining protocol were made to further optimize its performance. These adjustments were as follows:

- **Titers were adjusted, where deemed necessary, based on SS vs. MC assessment (see step 4 above and Supplemental Figure 6B).**
- Based on previous reports (8) of interference when multiple chemokine receptors are stained in the same panel, the staining of the chemokine receptors in the panel was optimized. Sequential vs. simultaneous staining was assessed to determine whether any improvements in resolution could be achieved. For some chemokine receptors (CCR5 and CXCR5 on B cells) an improvement was seen, while no differences were noted for CCR6 (Supplemental Figure 9A).
- Initial staining for TCRγδ yielded poor resolution of this population. Optimization of TCRγδ staining was achieved by the addition of the reagent at a different step in the staining process, subsequently improving the identification of this subpopulation of T cells (Supplemental Figure 9B).
- A significant amount of antibody aggregates were observed during the panel development with CD24 PE-Alexa Fluor 610 and CXCR5 BV750. Centrifugation of these reagents at 10,000 x g for 5 minutes decreased the presence of aggregates.

A summary of the reagents used in the panel, including their final titer, is provided in Supplemental Table 4.

**DATA ANALYSIS**

Manual gating of the main populations is displayed in Figure 1A. Detailed immunophenotyping of each cellular subset is presented in Supplemental Figure 10. While this display is commonly used to demonstrate the ability to resolve populations based on traditional gating strategies, manual data analysis of a 40-color panel is generally not practical as it is very time consuming, suffers from individual user bias, and compromises the ability to characterize subsets in multiple dimensions (9-11). Dimensionality reduction techniques for exploratory data analysis, such as Uniform Manifold Approximation and Projection (UMAP), have been used for mass cytometry data and single cell RNA-seq (12). These techniques can also be applied to fluorescent high-dimensional datasets, given that appropriate QC is performed prior to performing this kind of analysis.

Data from OMIP-069 were analyzed with the OMIQ platform (https://www.omiq.ai/, Figures 1B, and Supplemental Figure 11) utilizing the following pipeline. First, the scaling was adjusted to ensure greater than 99% of events were on scale for each channel and the negative population was unimodal around 0. The data were manually gated to remove aggregates, dead cells, debris, and CD45 negative events, and then the data were sub-sampled to include 400,000 CD45+ live singlets from each sample. Next, flowCut (13) was run to check for any aberrant regions of the file. FlowCut settings were as follows: all files used, all fluorescent channels and time selected, Segment = 500, Max Contin = 0.15, Mean of Means = 0.13, Max of Means = 0.15, Max of Valley Height = 0.15, Max Percent to Cut = 0.3, Low Density Removal = 0.1, no Gate Line set, Max Channel for Mean Range = 1, Max Channel for Mean SD = 2, no Flagged Rerun, Uniform of Time Check = 0.22, Remove Multi SD = 7. Results were as follows: largest continuous jump = 0.095, largest mean of % of range of means divided by range of data = 0.084, Max of % of range of means divided by range of data = 0.118, no events removed). Subsequently, a UMAP (14) analysis was performed to visualize the different sub-populations in groups. UMAP settings were as follows: all files used, all fluorescent parameters were used besides CD45 and Live/Dead, Neighbors = 80, Minimum Distance = 0.7, Components = 2, Metric = Euclidean, Learning Rate = 1, Epochs = 250, Random Seed = 9346, Embedding Initialization = spectral. Following the UMAP analysis, FlowSOM (15) was run to cluster the data. FlowSOM settings were as follows: all files used, clustering features CD4, CD8, CD45RA, CCR7, CD25, CD127, CD27, CD28, TCRγδ, CD16, CD1c, CD11c, IgD, IgM, and IgG, umap_1, umap_2, 625 clusters with xdim = 25 and ydim = 25, rlen = 10, Distance Metric = euclidian, consensus metaclustering with k = 100, Random Seed = 1337. After the FlowSOM analysis, the metaclusters were grouped into commonly recognized biological populations if possible. A heatmap was generated with the resulting populations and clustered hierarchically on all surface markers with a euclidean distance metric to indicate the similarity of the populations. This pipeline allows the FlowSOM clusters to be verified and translated into well-recognized populations via the heatmap, then those populations can be visualized on the UMAP parameters for ease of comparison between samples.
Supplemental Figure 9. Effects of Staining Conditions on Staining Quality

Optimization of the staining protocol was performed to improve the resolution of populations of interest. (A) Staining protocols were compared by overlaying MC cells stained simultaneously (gray line) or sequentially (black line) with chemokine receptor antibodies to determine differences in staining quality for these reagents. Indicated subpopulations were used to verify performance across multiple cell types. (B) Improvements in staining quality of TCRγδ+ cells: comparison of resolution when antibody was added as part of the full cocktail (left) or added separately (right). Data from two different donors is presented.
Supplemental Table 4. Final Selection of Reagents Used in OMIP-069

Staining reagents used in the final panel with antibody clone, manufacturer information, and final concentrations used in the staining protocol provided.

**OMIP-069: 40 Color Deep Immune Profiling**

<table>
<thead>
<tr>
<th>SPECIFICITY</th>
<th>FLUOROCHROME</th>
<th>CLONE</th>
<th>CATALOG #</th>
<th>VENDOR</th>
<th>Titer (ng/test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viability</td>
<td>LIVE/DEAD Blue</td>
<td>-</td>
<td>L34962</td>
<td>Thermo Fisher</td>
<td>5 µL of 1:40 dilution of stock</td>
</tr>
<tr>
<td>CD45</td>
<td>PerCP</td>
<td>2D1</td>
<td>368506</td>
<td>BioLegend</td>
<td>250</td>
</tr>
<tr>
<td>CD3</td>
<td>BV510</td>
<td>SK7</td>
<td>344828</td>
<td>BioLegend</td>
<td>400</td>
</tr>
<tr>
<td>CD4</td>
<td>cFluor YG584</td>
<td>SK3</td>
<td>R7-20041-100T</td>
<td>CYTEK</td>
<td>10</td>
</tr>
<tr>
<td>CD8</td>
<td>BUV805</td>
<td>SK1</td>
<td>612889</td>
<td>BD Biosciences</td>
<td>125</td>
</tr>
<tr>
<td>CD25</td>
<td>PE-Alexa Fluor 700</td>
<td>CD25-3G10</td>
<td>MHCD2524</td>
<td>Thermo Fisher</td>
<td>500</td>
</tr>
<tr>
<td>PD-1</td>
<td>BV785</td>
<td>EH12.2H7</td>
<td>329930</td>
<td>BioLegend</td>
<td>500</td>
</tr>
<tr>
<td>TCRγδ</td>
<td>PerCP-eFluor 710</td>
<td>B1.1</td>
<td>46-9959-42</td>
<td>Thermo Fisher</td>
<td>500</td>
</tr>
<tr>
<td>CD14</td>
<td>Spark Blue 550</td>
<td>63D3</td>
<td>367148</td>
<td>BioLegend</td>
<td>1000</td>
</tr>
<tr>
<td>CD16</td>
<td>BUV496</td>
<td>3G8</td>
<td>612944</td>
<td>BD Biosciences</td>
<td>250</td>
</tr>
<tr>
<td>CD11c</td>
<td>eFluor 450</td>
<td>3.9</td>
<td>48-0116-42</td>
<td>Thermo Fisher</td>
<td>500</td>
</tr>
<tr>
<td>CD19</td>
<td>Spark NIR 685</td>
<td>HIB19</td>
<td>302270</td>
<td>BioLegend</td>
<td>125</td>
</tr>
<tr>
<td>CD20</td>
<td>Pacific Orange</td>
<td>HI47</td>
<td>MHCD2030</td>
<td>Thermo Fisher</td>
<td>1000</td>
</tr>
<tr>
<td>CD24</td>
<td>PE-Alexa Fluor 610</td>
<td>SN3</td>
<td>MHCD2422</td>
<td>Thermo Fisher</td>
<td>500</td>
</tr>
<tr>
<td>CD39</td>
<td>BUV661</td>
<td>TU66</td>
<td>749967</td>
<td>BD Biosciences</td>
<td>1000</td>
</tr>
<tr>
<td>IgD</td>
<td>BV480</td>
<td>IA6-2</td>
<td>566138</td>
<td>BD Biosciences</td>
<td>125</td>
</tr>
<tr>
<td>IgG</td>
<td>BV605</td>
<td>G18-145</td>
<td>563246</td>
<td>BD Biosciences</td>
<td>125</td>
</tr>
<tr>
<td>IgM</td>
<td>BV570</td>
<td>MHM-88</td>
<td>314517</td>
<td>BioLegend</td>
<td>312.5</td>
</tr>
<tr>
<td>CD141</td>
<td>BB515</td>
<td>1A4</td>
<td>566017</td>
<td>BD Biosciences</td>
<td>250</td>
</tr>
<tr>
<td>CD1c</td>
<td>Alexa Fluor 647</td>
<td>L161</td>
<td>331510</td>
<td>BioLegend</td>
<td>250</td>
</tr>
<tr>
<td>CD123</td>
<td>Super Bright 436</td>
<td>6H6</td>
<td>62-1239-42</td>
<td>Thermo Fisher</td>
<td>125</td>
</tr>
<tr>
<td>CD2</td>
<td>PerCP-Cy5.5</td>
<td>TS1/8</td>
<td>309226</td>
<td>BioLegend</td>
<td>250</td>
</tr>
<tr>
<td>CD56</td>
<td>BUV737</td>
<td>NCAM16.2</td>
<td>564447</td>
<td>BD Biosciences</td>
<td>31.25</td>
</tr>
<tr>
<td>CCR7</td>
<td>BV421</td>
<td>G043H7</td>
<td>353208</td>
<td>BioLegend</td>
<td>700</td>
</tr>
<tr>
<td>CD27</td>
<td>APC-H7</td>
<td>M-T271</td>
<td>560222</td>
<td>BD Biosciences</td>
<td>250</td>
</tr>
<tr>
<td>CD45RA</td>
<td>BUV395</td>
<td>5H9</td>
<td>740315</td>
<td>BD Biosciences</td>
<td>250</td>
</tr>
<tr>
<td>CD95</td>
<td>PE-Cy5</td>
<td>DX2</td>
<td>305610</td>
<td>BioLegend</td>
<td>125</td>
</tr>
<tr>
<td>CD127</td>
<td>APC-R700</td>
<td>HIL-7-R-M21</td>
<td>565185</td>
<td>BD Biosciences</td>
<td>500</td>
</tr>
<tr>
<td>CD337</td>
<td>PE-Dazzle 594</td>
<td>P30-15</td>
<td>325231</td>
<td>BioLegend</td>
<td>500</td>
</tr>
<tr>
<td>CCR6</td>
<td>BV711</td>
<td>G034E3</td>
<td>353436</td>
<td>BioLegend</td>
<td>125</td>
</tr>
<tr>
<td>CCR5</td>
<td>BUV563</td>
<td>2D7/CCR5</td>
<td>741401</td>
<td>BD Biosciences</td>
<td>500</td>
</tr>
<tr>
<td>CXCR5</td>
<td>BV750</td>
<td>RF8B2</td>
<td>747111</td>
<td>BD Biosciences</td>
<td>250</td>
</tr>
<tr>
<td>CXCR3</td>
<td>PE-Cy7</td>
<td>G025H7</td>
<td>353720</td>
<td>BioLegend</td>
<td>1000</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>PE-Fire 810</td>
<td>L243</td>
<td>custom*</td>
<td>BioLegend</td>
<td>250</td>
</tr>
<tr>
<td>CD38</td>
<td>APC-Fire 810</td>
<td>HIT2</td>
<td>356643</td>
<td>BioLegend</td>
<td>500</td>
</tr>
<tr>
<td>CD57</td>
<td>FITC</td>
<td>HNK-1</td>
<td>359604</td>
<td>BioLegend</td>
<td>250</td>
</tr>
<tr>
<td>CD28</td>
<td>BV650</td>
<td>CD28.2</td>
<td>302946</td>
<td>BioLegend</td>
<td>250</td>
</tr>
<tr>
<td>CD159a</td>
<td>APC</td>
<td>REA110</td>
<td>130-113-563</td>
<td>Miltenyi</td>
<td>150</td>
</tr>
<tr>
<td>CD159c</td>
<td>PE</td>
<td>REA205</td>
<td>130-119-776</td>
<td>Miltenyi</td>
<td>200</td>
</tr>
<tr>
<td>CD314</td>
<td>BUV615</td>
<td>1D11</td>
<td>751232</td>
<td>BD Biosciences</td>
<td>1000</td>
</tr>
</tbody>
</table>

* Custom conjugation is available through BioLegend
OMIP-069: 40 Color Deep Immune Profiling

Dendritic Cells

- CD56 BUV737
- CD19 Spark NIR 685
- CCR5 BUV563
- CXCR3 PE-Cy7
- CD45RA BUV395
- CD38 APC-Fire 810
- CD14 Spark Blue 550
- HLA-DR PE-Fire 810
- CD123 Super Bright 436
- CD11c eFluor 450
- CD141 BB515
- CD1c Alexa Fluor 647

NK Cells

- CD3 TCRγδ
- CD56 BUV737
- HLA-DR PE-Fire 810
- CD16 BUV496
- CD161 BB515
- CD1c Alexa Fluor 647
- CD141 BB515
- CD16 BUV496
- CD163 BB515
- CD314 BUV615
- CD159a APC
- CD8 BUV805

Dendritic Cells: Donor 3458

NK Cells: Donor 5036
Supplemental Figure 10. Deep Immunophenotyping of All Cellular Subsets
Following the gating scheme presented in Figure 1A, the different cellular subsets were further characterized by manual gating. For each main population, the main markers that showed different levels of expression across the various subsets of that specific population are presented. Data presented corresponds to Donor 4559, as in Figure 1A. For the Tregs, DCs and NK populations, data from an additional donor is presented to illustrate observed difference in level of expression of certain markers.
Supplemental Figure 11. High Dimensional Data Reduction of 40-Color Panel
Overview showing the expression of phenotypic markers on PBMCs in several unsupervised analyses. (A) Hierarchically clustered heatmap displaying the marker expressions of manually labeled FlowSOM clusters from four concatenated samples. The marker expression intensity is displayed on a scale from white (negative) to blue (positive). Each column's max and min are mapped to this scale so the values change between markers, consequently the scale is labeled with – and + to indicate relative magnitude. (B) Visualization of the phenotypic variation across all PBMC subsets using UMAP. Marker expression intensity is indicated by the scale bar to the right of each plot, where red is high and blue is low.
OMIP-069: 40 Color Deep Immune Profiling
STAINING PROTOCOL

Materials and Reagents
- 12x75 mm (5 ml) Falcon® FACS tubes: Corning catalog #352063
- RPMI: Sigma catalog # R8758
- Fetal Bovine Serum (FBS): Gibco catalog #16000-036
- Penicillin-Streptomycin: Gibco catalog #15640-055
- PBS: Gibco catalog #20012-005
- Brilliant Staining buffer: BD Biosciences, catalog #563794
- True-Stain Monocyte Blocker™: BioLegend catalog #426101
- UltraComp eBeads™ Compensation Beads: Thermo Fisher, catalog #01-2222-41
- Wash/Stain Buffer: BD Stain Buffer (BSA) catalog #554657
- Antibodies specified in Supplemental Table 4

Cryopreserved PBMCs were purchased from AllCells (www.allcells.com, California USA). Different donors were used throughout the panel development process.

Prepared buffers: complete RPMI: add 50 ml of FBS, 5 ml of Penicillin-Streptomycin into 500 ml of RPMI 1640 (with L-glutamine and sodium bicarbonate)

Thawing PBMCs

Note: Handling of human blood components should be done in accordance with regional and institutional Biosafety policies and/or requirements.

1. Pre-warm complete RPMI at 37°C for at least 30 minutes.
2. Thaw cells as quickly as possible.
   a. Thaw cryo-vial (25x10⁶ cells) in 37°C water bath, until only small piece of ice remains.
   b. Transfer contents of cryo-vial to 50 mL conical tube.
   c. Add 1 ml of warm complete RPMI to cryo-vial. Leave aside until step f.
   d. Drop-by-drop add 5 ml of warm complete RPMI to the cells in the 50 mL tube. While adding, gently mix the 50 mL tube (with a pipette in one hand and in the other the 50 mL tube, add the complete RPMI while you gently swirl the tube).
   e. After first 5 ml of complete RPMI have been added, add the next 5 ml a little bit faster (a few drops at a time).
   f. After 10 ml have been added, pour the contents of the cryo-vial into the 50 mL tube.
   g. Add additional volume of complete RPMI to complete to 20 ml.
3. Spin at 400 x g for 8 minutes.
4. Decant supernatant carefully without disturbing the pellet.
5. Gently resuspend pellet in 2 ml of warm complete RPMI.
6. Complete to 20 ml.
7. Repeat steps 3 and 4.
8. Resuspend in 7.5 ml of complete RPMI or to an approximate concentration of 3.5x10⁶/ml.
9. Leave in incubator until ready to proceed (rest is not necessary, but once staining has begun, samples will need to be processed without delay).

Viability Dye and Antibody Preparation

1. Thaw aliquot of Live/Dead Blue (dried preparation is resuspended in DMSO following the manufacturer recommendation and 7 μl aliquots are stored at -20°C).
2. Transfer 5 μl of viability dye to a larger Eppendorf and add 195 μl 1X PBS (1:40 dilution).
3. Keep in dark until ready to use.
4. Prepare antibody dilutions as needed.
5. Prepare a master mix of all antibodies in brilliant stain buffer EXCEPT CCR5, CXCR5, and TCRγδ (see Supplemental Figure 9).

Staining

1. Label 12x75 mm (5 ml) FACS tubes: unstained, SS controls, and MC tubes.
2. Add 700 μl of cell suspension to each MC tube (approximately 2x10⁶ cells, to be able to collect enough events for very rare populations).
3. Add 100 μL of cells (approximately 3x10^5 cells) to each of the SS and unstained controls.  
   Note: Ideally, all controls should be cells, however, some antibody reagents showed no difference between cells and beads as reference controls, and in those cases, beads can be used. In this protocol, we used UltraComp eBeads™ Compensation Beads from ThermoFisher, however, beads from other manufacturers may perform differently. See step 2 under Panel Testing above.
4. MC and SS viability tubes need to be washed with PBS only.  
   Note: Viability dye is an amine reactive dye and will be bound by any proteins in the buffer, so it is important to make sure the wash buffer is free of protein.
5. All other SS controls and MC tubes are washed with wash buffer, 3 ml per tube.
6. Spin at 500 x g for 5 minutes.
7. Carefully decant supernatant.
8. Add 5 μl of viability dye dilution to MC AND Viability SS control; vortex and incubate for 15 minutes at room temperature in the dark.
9. In the meantime, start staining SS controls with the pre-determined optimal amount of antibody.
10. After 15 minute incubation, wash MC and SS viability tubes with wash buffer.
11. Repeat steps 6 and 7.
12. Add 300 μl of wash buffer to SS viability tube, vortex, store at 4°C.
14. Add 5 μl of True-Stain Monocyte Blocker; vortex.
15. Add anti-TCRγδ; vortex.
16. Incubate for 10 minutes at room temperature in the dark.
17. Add anti-CXCR5 and anti-CCR5; vortex.
18. Incubate for 10 minutes at room temperature in the dark.
19. Add the remainder of antibodies from the MC mix cocktail; vortex.
20. Incubate at room temperature in the dark for 30 minutes.
21. Finish staining/washing SS controls.
22. Wash all tubes with 3 ml of wash buffer.
23. Decant supernatant carefully, then resuspend the pellet.
24. Add 300 μl of 1% paraformaldehyde (PFA) in PBS to all tubes, including SS control tubes; vortex.  
   Note: It is very important to treat the SS controls in the same manner as the MC samples, including the fixation step. This is true whether beads or cells are used as SS controls. Fluorochrome emission properties can be slightly altered depending on their microenvironment. For accurate unmixing/compensation, SS controls need to be treated exactly the same as the MC stained sample. If necessary due to biosafety issues, 4% PFA can be used. Some reduction in intensity for some markers may occur after fixation with this high concentration of PFA as described in the literature (16). CD45RA for example is one of the markers that is impacted, but the resolution with the conjugate in this panel should still be optimal.
25. Incubate for 20 minutes at room temperature.
26. Repeat steps 6 and 7.
27. Resuspend pellet in 400 μl of wash buffer.
28. Store at 4°C protected from light until ready to acquire on the instrument.

REFERENCES